Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | GLA | P06280 | 2/20 | 0.51 |
| ▸ | CASP1 | P29466 | 1/20 | 0.51 |
| ▸ | CASP7 | P55210 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | CFTR | P13569 | 3/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3115872 | 0.98 | GAA (0.64) | GAAALDH1A1KDM4EHSD17B10MAPT | |
| SCHEMBL38655411 | 0.86 | GAA (0.54) | GAAALDH1A1KDM4EHSD17B10MAPT | |
| SCHEMBL31633499 | 0.85 | GAA (0.61) | GAAALDH1A1KDM4EHSD17B10MAPT | |
| SCHEMBL193418 | 0.85 | GAA (0.61) | GAAALDH1A1KDM4EHSD17B10MAPT | |
| Hydrochloric Acid SCHEMBL6162273 | 0.84 | GAA (0.59) | GAAALDH1A1KDM4EHSD17B10MAPT | |
| SCHEMBL1403643 | 0.82 | GAA (0.72) | GAAALDH1A1KDM4EHSD17B10MAPT | |
| SCHEMBL7623605 | 0.81 | GAA (0.70) | GAAALDH1A1KDM4EHSD17B10MAPT | |
| SCHEMBL523258 | 0.81 | CES2 (0.61) | GAAALDH1A1KDM4EMAPTCA12 | |
| SCHEMBL14012584 | 0.81 | CES2 (0.61) | GAAALDH1A1KDM4EMAPTCA12 | |
| SCHEMBL2926607 | 0.81 | GAA (0.70) | GAAALDH1A1KDM4EHSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 560 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637426-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2026-05-26 | — | — | US | disclosed |
| CN-122036605-A | Antagonists of GPR39 proteins | 俄勒冈健康科学大学 | 2026-05-15 | — | — | CN | disclosed |
| US-20260132121-A1 | INHIBITORS OF RIPK2 AND MEDICAL USES THEREOF | ODYSSEY THERAPEUTICS INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12624018-B1 | Inhibitors of RIPK2 and medical uses thereof | ODYSSEY THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-12624028-B2 | 1H-pyrazolo[4,3-G]isoquinoline and 1H-pyrazolo[4,3-g]quinoline derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260103455-A1 | ULK3 INHIBITORS AND USES THEREOF | H LEE MOFFITT CANCER CT & RES (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4482583-B1 | ZWITTERIONIC ANTIBACTERIAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2026-04-01 | — | — | EP | disclosed |
| US-12590105-B2 | KRas G12C inhibitors | ELI LILLY AND COMPANY (US) | 2026-03-31 | — | — | US | disclosed |
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4652161-A1 | 2,4-DIANILINOPYRIMIDINE-BASED AURORA-A KINASE SELECTIVE DEGRADATION INDUCING COMPOUNDS | Uppthera, Inc. (KR) | 2025-11-26 | — | — | EP | disclosed |
| WO-2005012280-A1 | ALKYNYL ARYL CARBOXAMIDES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2005-02-10 | — | — | WO | disclosed |
| WO-2005012288-A1 | BICYCLIC IMIDAZOL DERIVATIVES AGAINST FLAVIVIRIDAE | GENELABS TECHNOLOGIES, INC (US) | 2005-02-10 | — | — | WO | disclosed |
| WO-2004054974-A2 | PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
| WO-2004037243-A2 | METHODS OF TREATMENT DURING VASCULAR PROCEDURES | ALLERGAN, INC. (US) | 2004-05-06 | — | — | WO | disclosed |
| US-20040077710-A1 | Methods of treatment during vascular procedures | ALLERGAN, INC. | 2004-04-22 | — | — | US | disclosed |
| US-20040034012-A1 | 1,4,5,6-Tetrahydroimidazo[4,5-d]diazepine derivatives or salts thereof | ASTELLAS PHARMA INC. (JP) | 2004-02-19 | — | — | US | disclosed |
| WO-2004014900-A1 | BENZIMIDAZOLES AND BENZOTHIAZOLES AS INHIBITORS OF MAP KINASE | ELI LILLY AND COMPANY (US) | 2004-02-19 | — | — | WO | disclosed |
| EP-1338597-A1 | 1,4,5,6-TETRAHYDROIMIDAZO 4,5-D]DIAZEPINE DERIVATIVES OR SALTS THEREOF | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-08-27 | — | — | EP | disclosed |
| US-4333940-A | Ring-fluorinated 4-(monosubstituted-amino) phenyl compounds in inhibiting atherosclerotic lesion development | AMERICAN CYANAMID COMPANY (US) | 1982-06-08 | — | — | US | disclosed |
| US-4243609-A | ANTILIPEMIC AGENTS, ANTIATHEROSCLEROTIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1981-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT1, PRMT5, PRMT6 | GAA 4402/4885ALDH1A1 3522/4885KDM4E 147/4885 |
| US-12590105-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | GAA 4357/4885ALDH1A1 2890/4885KDM4E 2904/4885 |
| US-20040077710-A1 | Methods of treatment during vascular procedures | RARA, RARB, RXRA | GAA 1065/4885ALDH1A1 533/4885KDM4E 2566/4885 |
| US-20260132121-A1 | INHIBITORS OF RIPK2 AND MEDICAL USES THEREOF | RIPK1, RIPK2, RIPK4 | GAA 3362/4885ALDH1A1 4827/4885KDM4E 2182/4885 |
| US-12637426-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP1, USP10 | GAA 2633/4885ALDH1A1 1185/4885KDM4E 627/4885 |
| US-12624028-B2 | 1H-pyrazolo[4,3-G]isoquinoline and 1H-pyrazolo[4,3-g]quinoline derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD) | SERPINA2, SERPINC1, SERPINH1 | GAA 847/4885ALDH1A1 2048/4885KDM4E 4868/4885 |
| US-12624018-B1 | Inhibitors of RIPK2 and medical uses thereof | RIPK2, RIPK1, RIPK4 | GAA 3350/4885ALDH1A1 4801/4885KDM4E 3070/4885 |
| US-20260103455-A1 | ULK3 INHIBITORS AND USES THEREOF | ULK3, ULK1, ULK2 | GAA 4116/4885ALDH1A1 3985/4885KDM4E 1423/4885 |
| US-20040034012-A1 | 1,4,5,6-Tetrahydroimidazo[4,5-d]diazepine derivatives or salts thereof | AVPR1B, AVPR2, AVPR1A | GAA 4582/4885ALDH1A1 1825/4885KDM4E 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.